AU8548198A - Use of transcription factor brn-3a - Google Patents

Use of transcription factor brn-3a Download PDF

Info

Publication number
AU8548198A
AU8548198A AU85481/98A AU8548198A AU8548198A AU 8548198 A AU8548198 A AU 8548198A AU 85481/98 A AU85481/98 A AU 85481/98A AU 8548198 A AU8548198 A AU 8548198A AU 8548198 A AU8548198 A AU 8548198A
Authority
AU
Australia
Prior art keywords
brn
vector
polypeptide
polynucleotide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU85481/98A
Other languages
English (en)
Inventor
David Seymour Latchman
Martin Damian Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovex Ltd
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9715823.2A external-priority patent/GB9715823D0/en
Application filed by Biovex Ltd filed Critical Biovex Ltd
Publication of AU8548198A publication Critical patent/AU8548198A/en
Assigned to BIOVEX LIMITED reassignment BIOVEX LIMITED Amend patent request/document other than specification (104) Assignors: NEUROVEX LIMITED
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU85481/98A 1997-07-25 1998-07-27 Use of transcription factor brn-3a Abandoned AU8548198A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9715823 1997-07-25
GBGB9715823.2A GB9715823D0 (en) 1997-07-25 1997-07-25 Use of transcription factor BRN-3A
US98847697A 1997-12-10 1997-12-10
US08988476 1997-12-10
PCT/GB1998/002228 WO1999005272A1 (en) 1997-07-25 1998-07-27 Use of transcription factor brn-3a

Publications (1)

Publication Number Publication Date
AU8548198A true AU8548198A (en) 1999-02-16

Family

ID=26311947

Family Applications (1)

Application Number Title Priority Date Filing Date
AU85481/98A Abandoned AU8548198A (en) 1997-07-25 1998-07-27 Use of transcription factor brn-3a

Country Status (6)

Country Link
EP (1) EP1003859A1 (ja)
JP (1) JP2001511344A (ja)
AU (1) AU8548198A (ja)
CA (1) CA2298107A1 (ja)
IL (1) IL134210A0 (ja)
WO (1) WO1999005272A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9819999D0 (en) * 1998-09-14 1998-11-04 Univ London Treatment of cancer
EP1151094A1 (en) * 1998-12-07 2001-11-07 University College London Cervical cancer treatment
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
KR100820072B1 (ko) * 2002-12-28 2008-04-10 (주)아모레퍼시픽 진세노사이드 Ｆ1을 유효성분으로 하는 Ｂｃｌ-2 발현조절제
JP3870921B2 (ja) 2003-04-01 2007-01-24 セイコーエプソン株式会社 非接触識別タグ
KR100868905B1 (ko) * 2004-03-26 2008-11-14 (주)아모레퍼시픽 진세노사이드 ｆ1과 ｅｇｃｇ을 함유한 자외선 조사로유도되는 피부손상 방지용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof

Also Published As

Publication number Publication date
IL134210A0 (en) 2001-04-30
JP2001511344A (ja) 2001-08-14
WO1999005272A1 (en) 1999-02-04
WO1999005272A9 (en) 1999-10-28
CA2298107A1 (en) 1999-02-04
EP1003859A1 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
US6719982B1 (en) Mutant herpes simplex viruses and uses thereof
Lamballe et al. trkC encodes multiple neurotrophin‐3 receptors with distinct biological properties and substrate specificities.
EP0675961B1 (en) Treatment of tumorigenic disease with a modified HSV
US6106826A (en) Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
AU726645B2 (en) HSV strain lacking functional ICP27 and ICP34.5 Genes
AU749064B2 (en) Eukaryotic gene expression cassette and uses thereof
Adamus et al. Anti-apoptotic effects of CNTF gene transfer on photoreceptor degeneration in experimental antibody-induced retinopathy
AU8548198A (en) Use of transcription factor brn-3a
CZ288882B6 (cs) Polynukleotid, antimediátorový polynukleotid, polypeptid kódovaný uvedeným polynukleotidem, vektor obsahující uvedený polynukleotid, farmaceutická kompozice obsahující uvedený polynukleotid nebo antimediátorový polynukleotid nebo polypeptid nebo vektor a jejich použití pro přípravu farmaceutické kompozice
US20040110711A1 (en) Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
US6194175B1 (en) Nucleic acids encoding truncated forms of inhibitory kappa B protein
WO1997010349A1 (en) Materials and methods for treating neurodegenerative diseases and for screening for candidate apoptosis inhibitors and inducers
Yazaki et al. Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration
AU783691B2 (en) Replication incompetent herpes virus vectors
WO2003071872A1 (en) Novel treatment of neurodegenerative diseases by altering levels of trkb isoforms and/or trkc isoforms
WO1999036559A1 (en) Viral vectors expressing self-polymerizing neuronal intermediate filaments and their use
WO1999053043A2 (en) Herpes simplex virus latency associated transcript polypeptides
MXPA99006454A (en) Eukaryotic gene expression cassette and uses thereof
WO2003087357A2 (en) Nucleic acid comprising retinal-specific regulatory region

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: BIOVEX LIMITED

Free format text: FORMER NAME: NEUROVEX LIMITED

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted